Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954094 · ClinicalTrials.gov registry record
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
A clinical trial of Hepatocellular Cancer, sponsored by Target PharmaSolutions.
- Active
- Registry status
- 10,000
- Enrollment target
- 20
- Study locations
NCT02954094: Active study of Hepatocellular Cancer, sponsored by Target PharmaSolutions.
NCT02954094 is a study of Hepatocellular Cancer that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 10,000 participants, above the 317-participant average among 15 other Hepatocellular Cancer trials with a reported enrollment target (3055% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02954094, a study of Hepatocellular Cancer, is active but no longer recruiting, sponsored by Target PharmaSolutions.
- ACTIVE NOT RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Conditions Studied
Study Locations (20)
California
- University of Southern California/Norris Comprehensive Cancer Center - Los Angeles
- Stanford University - Palo Alto
- California Liver Research Institute - Pasadena
- University of California-Davis - Sacramento
- University of California - San Francisco
Florida
- Gastro Florida - Clearwater
- University of Florida Hepatology Research at CTRB - Gainesville
- University of Florida Health Gastroenterology - Jacksonville
- Schiff Center for Liver Diseases/University of Miami - Miami
- Tampa General Medical Group - Tampa
Georgia
- Piedmont Atlanta Hospital - Atlanta
- Piedmont Cancer Institute - Atlanta
- Emory University Hospital - Atlanta
Illinois
- Northwestern University Division of Gastroenterology and Hepatology - Chicago
- Rush University Medical Center - Chicago
- University of Chicago - Chicago
Arizona
- Banner University Medical Center - Phoenix
Arkansas
- University of Arkansas - Little Rock
District of Columbia
- Georgetown University - Washington D.C.
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2016-12 |
| Est. Completion | 2027-02 |
What the registry record for NCT02954094 still lists
NCT02954094 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 317-participant average among 15 other Hepatocellular Cancer trials with a reported enrollment target (3055% higher).
The record links to 1 condition, with Hepatocellular Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02954094 names 20 study sites across 8 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02954094 about?
NCT02954094 is a clinical study titled "A Longitudinal Observational Study of the Natural History and Management of Patients With HCC". TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectru...
What is the current status of trial NCT02954094?
This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2016-12. Estimated completion is 2027-02.
What conditions does trial NCT02954094 study?
This clinical trial studies the following conditions: Hepatocellular Cancer.
Who is sponsoring clinical trial NCT02954094?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02954094 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02954094's enrollment target sits among peer trials
10,000 1st of 15 higher than 15 of 15 other Hepatocellular Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
RECRUITING
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
RECRUITING · Phase 1
-
SIRT With Tremelimumab and Durvalumab for Resectable HCC
RECRUITING · Phase 1
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia